Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 131 to 140 of 279 total matches.

In Brief: Prevention of Measles

   
The Medical Letter on Drugs and Therapeutics • Jun 09, 2025  (Issue 1730)
to neomycin (M-M-R II and Priorix) or hypersensitivity to gelatin (M-M-R II). VACCINE ADVERSE EFFECTS — Pain ...
According to the Centers for Disease Control (CDC), as of April 24 there have been 844 confirmed cases of measles in the US in 2025; 11% of cases have resulted in hospitalization and 3 patients have died. The majority of cases (96%) have been in unvaccinated persons or in those whose vaccination history was unknown
Med Lett Drugs Ther. 2025 Jun 9;67(1730):94-5   doi:10.58347/tml.2025.1730d |  Show IntroductionHide Introduction

Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
) has been available since 2018 for treatment of moderate to severe pain associated with endometriosis.1 The GnRH ...
Oriahnn (Abbvie), a fixed-dose combination of the gonadotropin-releasing hormone (GnRH) receptor antagonist elagolix, the estrogen estradiol, and the progestin norethindrone acetate copackaged with elagolix alone, has been approved by the FDA for oral treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It is the first product to be approved in the US for this indication. Elagolix (Orilissa) has been available since 2018 for treatment of moderate to severe pain associated with endometriosis. The GnRH receptor antagonist...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):51-2 |  Show IntroductionHide Introduction

MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
in ≥20% of patients) were pain and erythema at the injection site, malaise, and myalgia. Among subjects ...
The FDA has licensed MenQuadfi (Sanofi Pasteur), a quadrivalent polysaccharide conjugate vaccine that uses tetanus toxoid as a protein carrier, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y (MenACWY) in persons ≥2 years old.
Med Lett Drugs Ther. 2021 May 17;63(1624):78-80 |  Show IntroductionHide Introduction

Prevention and Treatment of Monkeypox

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022  (Issue 1658)
and at least every 10 years for exposure to less virulent orthopoxviruses Common adverse effects Pain ...
An outbreak of monkeypox has recently spread around the globe and across the US. Updated information about the current outbreak is available from the CDC.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):137-9 |  Show IntroductionHide Introduction

A New RSV Vaccine (mResvia) for Adults ≥60 Years Old

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
). ▶ Adverse Effects: Most common are injection-site pain, axillary swelling or tenderness, fatigue, headache ...
TThe FDA has licensed mResvia (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first mRNA vaccine to be licensed in the US for this indication. Two recombinant RSV vaccines, Arexvy and Abrysvo, are also available for prevention of RSV LRTD. Arexvy is approved for use in adults ≥50 years old. Abrysvo is approved for use in adults ≥60 years old and in pregnant women to prevent RSV LRTD in their infants.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):166-8   doi:10.58347/tml.2024.1713d |  Show IntroductionHide Introduction

Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023  (Issue 1686)
often with Arexvy than placebo in the pivotal clinical trial included injection-site pain (60.9% vs ...
Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old. They are the first RSV vaccines to be approved in the US. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent LRTD caused by RSV in their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6   doi:10.58347/tml.2023.1686a |  Show IntroductionHide Introduction

In Brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021  (Issue 1629)
Adolescents and young adults who experience acute chest pain, shortness of breath, or palpitations after ...
On June 25, 2021, the FDA added a warning to the Fact Sheets for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) about an increased risk of myocarditis and pericarditis following administration of the vaccines.
Med Lett Drugs Ther. 2021 Jul 26;63(1629):e9 |  Show IntroductionHide Introduction

In Brief: Shingrix for Immunocompromised Adults

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
, fever, GI symptoms, and injection-site pain, redness, and swelling are common. Severe local reactions ...
The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine Shingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression. Shingrix has been licensed for herpes zoster prevention in adults ≥50 years old since 2017.1 It is the only VZV vaccine currently available in the US; Zostavax, a live-attenuated VZV vaccine, was withdrawn from the market in 2020.
Med Lett Drugs Ther. 2021 Aug 23;63(1631):129 |  Show IntroductionHide Introduction

In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
, musculoskeletal pain, pruritus, diarrhea, rash, pyrexia, and nausea. Infusion-related reactions and severe ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed death receptor-1 (PD-1) blocking antibody, has received accelerated approval from the FDA for treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in adults. Accelerated approval of the drug was based on the response rate and duration of response. Retifanlimab is the third drug to be approved in the US for treatment of MCC; pembrolizumab (Keytruda), a PD-1 blocking antibody, is approved for the same indication as retifanlimab in patients ≥12 years old and avelumab (Bavencio), a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4   doi:10.58347/tml.2023.1674h |  Show IntroductionHide Introduction

Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
effects: diarrhea is most common (lowering the dose may help), abdominal pain, flatulence, abdominal ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3   doi:10.58347/tml.2025.1721e |  Show IntroductionHide Introduction